Sign inJoin waitlistJoin the waitlist

Megan Waldrop

Program Director · Nationwide Children's Hospital

Credentials: · ·

History

Ohio State University Hospital
2015–2016
Nationwide Children's Hospital
2014–2015
Pediatrics
University of California
2011–2014
Albany Medical College
2007–2011

Research

Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes
PEDIATRICS · 2020 · First of 18 authors · Corresponding · 102 citations
Current clinical applications of AAV-mediated gene therapy
Review · Molecular Therapy · 2025 · 87 citations
Update in Duchenne and Becker muscular dystrophy
Review · Current Opinion in Neurology · 2019 · First of 2 authors · 83 citations

Kevin Flanigan
26 papers
Anne Connolly
12 papers
Megan Iammarino
8 papers
Chang-Yong Tsao
7 papers
Alayne Meyer
6 papers
Jerry Mendell
6 papers
Richard Shell
5 papers
Garey Noritz
4 papers
Shannon Chagat
4 papers
Stefan Nicolau
4 papers · 3 as a resident
SC
Steven Chessler
4 papers
Carsten Bonnemann
3 papers

Clinical trials

Gene Therapy for IGHMBP2-Related Diseases
Principal investigator · Enrolling by invitation · Phase 1, Phase 2
Megan Waldrop
2021–2030
AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications.
Principal investigator · Completed · Phase 1, Phase 2
Megan Waldrop
2020–2025
Spironolactone Versus Prednisolone in DMD
Principal investigator · Terminated · Phase 1
Kevin Flanigan
2018–2021
The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy
Site PI · Recruiting
University of Rochester
2026–2029